VERA

Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints

Vera Therapeutics: Why I'm Sticking With 'Hold' Despite Today's Positive Trutakna Data

What's Going on With Vera Therapeutics Stock on Tuesday?

Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results

Why is Vera Therapeutics stock reversing its premarket gains?

TD Cowen reiterates Buy on Vera Therapeutics stock on kidney data

Vera Therapeutics stock maintained at Strong Buy by Raymond James

Vera Stock Slides Despite Positive Phase 3 Results

Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints

VERA Stock Jumps 16% Premarket – Trutakna Cuts Kidney Disease Progression Risk By 76%, Full FDA Filing Planned In Q4

Why is Vera Therapeutics stock surging today?

Vera Therapeutics stock jumps on positive trial results

Vera Therapeutics options activity points to institutional bullish call spread on September strikes

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch

Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?